依库珠单抗治疗难治性重症肌无力的干预后状态:REGAIN及其开放标签扩展研究
该研究评估抗乙酰胆碱受体阳性(AChR+)难治性全身型重症肌无力(gMG)患者接受依库珠单抗治疗后能否达到MGFA干预后状态中的轻微表现(MM)。REGAIN随机对照试验第26周时,依库珠单抗组MM达标率高于安慰剂组(25.0% vs 13.3%;共同OR 2.3;95%CI 1.1-4.5);开放标签扩展至第130周时,57.3%患者达到MM。
要点
- REGAIN第26周依库珠单抗组MM达标率25.0%,高于安慰剂组的13.3%。
- 开放标签扩展至130周,88.0%患者达改善状态,57.3%达MM状态。
- 安全性特征与已知一致,未发现新安全信号。
核心结论
- 依库珠单抗使AChR+难治性gMG患者快速且持续达到MM状态。
- 结果支持在该既往难以治疗的人群中使用依库珠单抗。
研究设计与样本
- REGAIN随机对照试验及其开放标签扩展的三级终点分析。
- 117例完成REGAIN并进入开放标签研究者纳入分析(依库珠单抗/依库珠单抗56例;安慰剂/依库珠单抗61例)。
主要发现
- REGAIN第26周,依库珠单抗组改善状态达标率60.7%,安慰剂组41.7%。
- REGAIN第26周,依库珠单抗组MM达标率25.0%,安慰剂组13.3%(共同OR 2.3;95%CI 1.1-4.5)。
- 依库珠单抗治疗130周后,88.0%患者达改善状态,57.3%达MM状态。
- 安全性特征与已知一致,未检测到新安全信号。
关键数值与推荐
- MGFA干预后状态评估包括改善、不变、恶化、MM及药物缓解,于REGAIN及开放标签研究至第130周的既定时间点评估。
- 证据等级为Class II:依库珠单抗治疗26周后25.0%的AChR+难治性gMG成人达到MM,安慰剂组为13.3%。
临床怎么用
- 对AChR+难治性gMG患者,可考虑依库珠单抗以争取快速达到MM并维持长期获益。
- 治疗期间按MGFA干预后状态定期评估疗效,并持续监测安全性。
局限性
- 本文为三级终点分析,未报告随机化盲法等设计细节。
- 未报告长期扩展阶段的对照数据及不良事件具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo.
引用
- Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2020. PMID: 33229455. doi:10.1212/WNL.0000000000011207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。